Roberto Cubeddu, MD
Interventional Cardiology · Naples, FLNPI 1346395969
Payments from drug & device makers
Across 788 payments — averaging $2486.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1.6M
- Abbott$226K
- W. L. Gore & Associates, Inc.$112K
- Novartis$20K
- Cardiva Medical, Inc.$8K
- Arthrex$7K
- plus $13K from 29 others
What the payments were for
- Consulting fees$113,33950%
- Speaking & faculty fees$53,32523%
- Travel & lodging$29,47013%
- Food & beverage$31,13314%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 312 | $1,572,623 |
| Abbott | 221 | $226,137 |
| W. L. Gore & Associates, Inc. | 40 | $112,450 |
| Novartis | 19 | $20,142 |
| Cardiva Medical, Inc. | 18 | $7,886 |
| Arthrex | 15 | $7,178 |
| Boston Scientific | 46 | $2,951 |
| Medtronic(2 entities) | 25 | $2,719 |
| Abiomed | 28 | $2,347 |
| Biosense Webster, Inc. | 6 | $1,265 |
| Angiodynamics, Inc. | 5 | $491 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $359 |
| Atricure, Inc. | 2 | $294 |
| Shockwave Medical, Inc | 4 | $264 |
| Cvrx, Inc. | 3 | $241 |
| Vital Connect, Inc | 1 | $200 |
| ZOLL Circulation Inc | 2 | $184 |
| Livanova USA, Inc. | 2 | $158 |
| Inari Medical, Inc. | 2 | $151 |
| Philips North America LLC | 1 | $143 |
| Pfizer | 7 | $116 |
| Johnson & Johnson | 7 | $112 |
| Bolton Medical Inc | 2 | $111 |
| Biotronik Inc. | 1 | $108 |
| Siemens Medical Solutions USA, Inc. | 1 | $93 |
| Kestra Medical Technology Services, Inc. | 1 | $80 |
| GE HealthCare | 2 | $45 |
| Amgen | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Bayer | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Terumo Medical Corporation | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$73,630
- PASCAL$25,075
- Mitra Clip system$24,782
- EVOQUE$18,531
- MitraClip$16,604
- SavvyWire$14,616
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$7,060
- MitraClip System$6,799
- EP-WorkMate Recording System$4,800
- AMPLATZER Occluders$3,213
- GORE CARDIOFORM Septal Occluder$1,465
- CoreValve Evolut$1,363
- Impella$1,205
- Thermocool SF$760
- THERMOCOOL SMARTTOUCH$445
- Watchman$352
- PORTICO$350
- COREVALVE EVOLUT R$341
- LifeVest$309
- Tendyne Mitral Valve System$300
How this compares
$1,959,060 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $168,892 |
| EntrestoSacubitril/Valsartan | 80 | $79,936 |
| EliquisApixaban | 64 | $59,869 |
| FarxigaDapagliflozin Propanediol | 28 | $20,138 |
| XareltoRivaroxaban | 11 | $10,077 |
| Metoprolol Succinate | 122 | $1,435 |
| Torsemide | 38 | $1,161 |
| Ezetimibe | 26 | $702 |
| Amiodarone Hcl | 19 | $358 |
| Furosemide | 91 | $351 |
| Spironolactone | 57 | $341 |
| ClopidogrelClopidogrel Bisulfate | 24 | $338 |
| Rosuvastatin Calcium | 23 | $273 |
| Warfarin Sodium | 15 | $198 |
| Losartan Potassium | 11 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $20,142 | $79,93680 claims |
| PfizerEliquis | $116 | $59,86964 claims |
| Johnson & JohnsonXarelto | $112 | $10,07711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Naples
- Julian JavierNaples$1.7M
- Leandro PerezNaples$386K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.